NewsEpisurf Medical: Episealer® 24 months’ clinical study results accepted for publication in peer-reviewed scientific journal

Episurf Medical (NASDAQ: EPIS B) today announces that a peer-reviewed article with clinical data on 10 Episealer® knee implant patients with 24 months’ follow-up now is accepted for publication.

The publication with the title “A customized femoral resurfacing metal implant for focal chondral lesions – radiostereometric analysis and subjective outcome of the first ten patients” by Stålman, A., Sköldenberg, O., Martinez-Carranza, N., Högström, M. and Ryd, L. will be published in the journal Knee Surgery, Sports Traumatology, Arthroscopy and is shortly available online.

The study behind the publication is a multi-center clinical study conducted in Sweden with Dr Anders Stålman as principal investigator. The surgeries were performed between 2012 and 2014. The patients were followed-up with subjective outcome measures (VAS, Tegner, EQ5D and KOOS) and implant fixation was studied with RSA. The subjective outcome measures showed improvements that reached significance for VAS (p=< 0,001), Tegner (p=0,034) and the KOOS sub-scores Activities of Daily Living (p=0,0048), Sport and Recreation (p=0,034) and Quality of Life (p=0,037).

“This first publication from a clinical multi-center study with Episealer®, a customized focal knee resurfacing system, shows short-term implant safety and the patient related outcome measures show good to excellent results” says Anders Stålman, PhD, Senior Consultant, Capio Artro Clinic, Stockholm.

“This publication is very welcome for us, as high-quality peer-reviewed clinical evidence is a must for orthopaedic surgeons in their treatment decisions. This is a further and very important step forward to gain market shares for the Episealer®” comments Pål Ryfors, CEO, Episurf Medical.

For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69